Trial Profile
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines (PCV10 and PCV13) on Immunogenicity and Vaccine-serotype Carriage in Kenyan Infants
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms FPCV
- 03 Nov 2023 Planned End Date changed from 30 Apr 2023 to 30 Dec 2024.
- 23 Feb 2022 Planned End Date changed from 1 Dec 2021 to 30 Apr 2023.
- 23 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 31 Jul 2022.